Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.870
+0.020 (1.08%)
At close: May 12, 2025, 4:00 PM
1.880
+0.010 (0.53%)
After-hours: May 12, 2025, 7:56 PM EDT
Immutep Employees
Immutep had 31 employees as of June 30, 2014.
Employees
31
Change
n/a
Growth
n/a
Revenue / Employee
$97,395
Profits / Employee
-$875,690
Market Cap
269.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2014 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMMP News
- 4 days ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 5 weeks ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 3 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha
- 5 months ago - Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewsWire
- 5 months ago - Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 - GlobeNewsWire
- 6 months ago - Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients - Seeking Alpha
- 6 months ago - Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Benzinga